Hubei Jumpcan Pharmaceutical Co Ltd (600566) - Total Liabilities
Based on the latest financial reports, Hubei Jumpcan Pharmaceutical Co Ltd (600566) has total liabilities worth CN¥2.68 Billion CNY (≈ $391.55 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Hubei Jumpcan Pharmaceutical Co Ltd generate cash to assess how effectively this company generates cash.
Hubei Jumpcan Pharmaceutical Co Ltd - Total Liabilities Trend (1998–2024)
This chart illustrates how Hubei Jumpcan Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Hubei Jumpcan Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.
Hubei Jumpcan Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hubei Jumpcan Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ZoomInfo Technologies Inc
NASDAQ:ZI
|
USA | $4.90 Billion |
|
Spar Nord Bank
CO:SPNO
|
Denmark | Dkr128.66 Billion |
|
Kenon Holdings
TA:KEN
|
Israel | ILA1.75 Billion |
|
GCL System Integration Technology Co Ltd
SHE:002506
|
China | CN¥17.49 Billion |
|
Shanghai Wanye Enterprises Co Ltd
SHG:600641
|
China | CN¥3.46 Billion |
|
Avicopter PLC
SHG:600038
|
China | CN¥35.62 Billion |
|
Shanghai Huace Navigation Technology Ltd
SHE:300627
|
China | CN¥-4.01 Billion |
|
Benefit Systems SA
WAR:BFT
|
Poland | zł4.08 Billion |
Liability Composition Analysis (1998–2024)
This chart breaks down Hubei Jumpcan Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600566 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hubei Jumpcan Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hubei Jumpcan Pharmaceutical Co Ltd (1998–2024)
The table below shows the annual total liabilities of Hubei Jumpcan Pharmaceutical Co Ltd from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.73 Billion ≈ $546.27 Million |
-21.82% |
| 2023-12-31 | CN¥4.77 Billion ≈ $698.71 Million |
+31.59% |
| 2022-12-31 | CN¥3.63 Billion ≈ $530.99 Million |
+20.96% |
| 2021-12-31 | CN¥3.00 Billion ≈ $438.99 Million |
+8.99% |
| 2020-12-31 | CN¥2.75 Billion ≈ $402.80 Million |
+7.52% |
| 2019-12-31 | CN¥2.56 Billion ≈ $374.64 Million |
+9.43% |
| 2018-12-31 | CN¥2.34 Billion ≈ $342.34 Million |
+3.48% |
| 2017-12-31 | CN¥2.26 Billion ≈ $330.82 Million |
+73.89% |
| 2016-12-31 | CN¥1.30 Billion ≈ $190.25 Million |
+48.99% |
| 2015-12-31 | CN¥872.59 Million ≈ $127.69 Million |
-17.97% |
| 2014-12-31 | CN¥1.06 Billion ≈ $155.66 Million |
+23.40% |
| 2013-12-31 | CN¥862.04 Million ≈ $126.14 Million |
+71.70% |
| 2012-12-31 | CN¥502.07 Million ≈ $73.47 Million |
+15.42% |
| 2011-12-31 | CN¥435.00 Million ≈ $63.65 Million |
+26.86% |
| 2010-12-31 | CN¥342.89 Million ≈ $50.18 Million |
+6.04% |
| 2009-12-31 | CN¥323.37 Million ≈ $47.32 Million |
-0.02% |
| 2008-12-31 | CN¥323.43 Million ≈ $47.33 Million |
+6.57% |
| 2007-12-31 | CN¥303.49 Million ≈ $44.41 Million |
+0.93% |
| 2006-12-31 | CN¥300.69 Million ≈ $44.00 Million |
+19.34% |
| 2005-12-31 | CN¥251.96 Million ≈ $36.87 Million |
+12.49% |
| 2004-12-31 | CN¥223.98 Million ≈ $32.78 Million |
+21.78% |
| 2003-12-31 | CN¥183.92 Million ≈ $26.91 Million |
+24.13% |
| 2002-12-31 | CN¥148.17 Million ≈ $21.68 Million |
+11.34% |
| 2001-12-31 | CN¥133.08 Million ≈ $19.47 Million |
+59.61% |
| 2000-12-31 | CN¥83.37 Million ≈ $12.20 Million |
+17.06% |
| 1999-12-31 | CN¥71.23 Million ≈ $10.42 Million |
-8.44% |
| 1998-12-31 | CN¥77.79 Million ≈ $11.38 Million |
-- |
About Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of drugs in China. The company offers Chinese traditional and Western medicines, daily use chemicals, and medicine health products in various formulations. Its products are used in the areas of detoxification, digestive system, pediatric, respiratory system, nervous system, anti-infection, cardiovasc… Read more